Scientific Program

14 September 2022 (Wednesday), Day 1

10.00-18.00

Registration & Poster move in

13.00-13.30

Opening Ceremony

F. Altuntas, M. Lozano, M.A. Erkurt, S. Korkmaz, L. Pierelli

Plenary Session – Hall 1

Chairs: F. Altuntas, M. Lozano, C. Andersen

13.30-14.00

Cohn de Laval Award and Lecture
L. Guillevin

14.00-14.30

Helmut Borberg Award and Lecture

B. Stegmayr

14.30-15.30

Coffee Break & Poster Session 1

Plenary Session II – Apheresis in the covid era – Hall 1

Chairs: A. Ünal, A. Buser

15.30-16.00

Apheresis in Long-Haul COVID

Presenter

16.00-16.30

Is there a role of TPE in severe COVID-19 infection?
M. Lozano

16.30-17.00

Nurses perspective of apheresis in SARS-CoV-2 infected patients
L. Tjoelker

17.00-18.30

Welcome Reception – (open to all registrants)

15 September 2022 (Thursday), Day 2

Scientific Session I
Cellular Therapy: Apheresis and beyond – 1

Educational Session I
Basics of Apheresis

Chairs: S. Korkmaz, N. Worel

Chairs: C. Anderson, S. Çağırgan

Hall 1

Hall 2

09.00-09.30

Apheresis collection of the correct cells for CAR-Ts
M. Lozano

Basics of apheresis and equipment
H. Vrielink

09.30-10.00

CAR-T cell production in the academic center (regulations / quality / profit)
J. Delgado

Basic Physiology of Therapeutic Plazma Exchange
R. Weinstein

10.00-10.30

FACT/JACIE Standards for Cellular Therapy Collection facilities (CAR T-cells)
J. Schwartz

Apheresis Mathematics
L. Tjoelker

10.30-11.00

Coffee Break

Scientific Session II
Cellular Therapy: Apheresis and beyond – 2

Educational Session II
Quality and Compliance in Apheresis

Chairs: F. Altuntas, G. Leitner

Chairs: L. Ündar, M. Yağcı

Hall 1

Hall 2

11.00-11.30

Clinical use of CAR-T cells in treating ALL
S. Korkmaz

Qualification in Apheresis (QIA): a New Credential for Apheresis Professionals
C. Anderson

11.30-12.00

Clinical use of CAR-T-cells in Multiple Myeloma
C. Fernandez – Online

Therapeutic Apheresis Standards: Legal and Social Considerations (Quality in Apheresis Center)
D. Iskender

12.00-12.30

Novel applications of CAR-T technologies
J. Delgado

Update on Indications: The 8th ASFA Guidelines
J. Schwartz

12.30-13.30

Sponsored Lunch Symposium

Scientific Session III
Cellular Therapy: Apheresis and beyond – 3
Advances in managing benign disease

Scientific Session IV
Donor Apheres’s

Chairs: C. Webb, G. Öztürk

Chairs: G. Özet, H. Vrielink

Hall 1

Hall 2

13.30-14.00

Apheresis in the standard of care for sickle cell disease and new medical approaches
R. Sarode

Are we donating bone: impact of apheresis on bone density
L. Pierelli

14.00-14.30

Gene Therapy Approaches to Sickle Cell Disease
T. Ulaş

FGF23: the link between iron- and bone metabolism
K. le Poole

14.30-15.00

Mobilization for CD34+ collection in patients with Sickle Cell Disease
M. Pamukçuoğlu – Online

Are we donating iron: impact of apheresis on ferritin levels
L. Infanti

15.00-15.30

Coffee Break

Scientific Session V
Cellular Therapy: Apheresis and beyond – 4

Scientific Session IV
Hyperimmune Plasma Usage & WAA Registry

Chairs: L. Pierelli, M. Karakükçü

Chairs: H. Vrielink, A. Buser

Hall 1

Hall 2

15.30-16.00

Use of CD34+ cells in ALD / MLD in pediatric patients
E. Ünal

15.30-16.00 – COVID convalescent plasma: is there still a place for CCP?
R. Moog

16.00-16.30

Poor CD34+ Mobilizers: How to Manage?
N. Worel

16.00-16.30 – Anti-D challenges in low and middle income countries
A. Babynets

16.30-17.00

Plerixafor in the allo donor situation
J. Cid

16.30-16.40 – The first and other registries and why have one?
G. Rock

16.40-16.50 – History, update and future direction on the WAA registry
B. Stegmayr

16.50-17.00 – Open Discussion: The way forward for the WAA registry

17.00-17.15

Coffee Break

Plenary Abstract Scientific Session (Oral Presentations) – HALL 1
Including Abel-Rowntree-Turner Awardees – ESFH best abstract award – THRDS best abstract award

Chairs: F. Altuntas, M. Lozano, M.A. Erkurt

17.15-17.30

O-01: Use of Therapeutic Plasma Exchange in the Management of Crimean-Congo Hemorrhagic Fever: A Single-Center Experience.
E. E. Eren

17.30-17.45

O-02: Do Blood Groups Have An Effect On The Release Of Hematopoietic Stem Cells From The Bone Marrow Niche Into The Periphery?
E. Durmuşoğlu

17.45-18.00

O-03: Is There Any predictive Laboratory Parameter To Predict The Success Of Hemoadsorption In Sepsis?
S. Altuntas

18.00-18.15

O-04: Difference in CD34+ Collection Efficacy Between Non-Hodgkin Lymphoma and Multiple Myeloma
K. le Poole

18.15-18.30

O-05: Outcomes of Autologous Peripheral Stem Cell Transplantation in Hodgkin’s Lymphoma Patients: A Single Center Experience.
M. E. Erdoğan Yön

18.30-19.30

ESFH general assembly (ESFH members only)

16 September 2022 (Friday), Day 3

07.00-17.00

Registration

Breakfast with the Experts (first come, first served)

07.00-08.15

· Apheresis in LMICs (H. Vrielink)

· ECP procedures (C. Webb)

· Apheresis in pediatric patients (B.A. Aksoy)

· TTP (G. Rock)

· JACIE/FACT (N. Worel, J. Schwartz)

· CAR-T, CAR-B and CAR-NKs (F. Altuntas)

· Venous access (M-J. Mustieles)

Scientific Session VII
Vasculitis and Autoimmune Disease

Educational Session III
Extracorporeal Photopheresis

Chairs: W. Szpirt, S.K. Beşışık

Chairs: B. Turgut, N. Worel

Hall 1

Hall 2

08.30-09.00

Therapeutic apheresis in ANCA Associated Vasculitis: Current Status of Pexivas.
W. Szpirt

Indications for Photopheresis
E. Özdemir

09.00-09.30

Pulmonary hemorrhage, pulmonary renal syndrome and therapeutic plasma exchange

K le Poole

Ultra sound technology for venous access
M-J. Mustieles

09.30-10.00

ECP in autoimmune disorders
C. Webb

Current technology in ECP
M. Arat

10.00-10.30

Coffee Break

Scientific Session VIII
Thrombotic Microangiopathies

Scientific Abstract Session 2

Chairs: R. Sarode, G. Rock

Chairs: R. Weinstein, J. Schwartz

Hall 1

Hall 2

10.30-11.00

TTP in the Caplacizumab era
R. Sarode

10.30-10.45 – O-06: Adverse Reactions during TPE in Liver Disease Patients

M. Bajpai

11.00-11.30

Biomarkers of response and prognosis in TTP
G. Rock

10.45-11.00 – O-07: Plasmapheresis Experience in COVID-19

M. A. Karaselek

11.30-12.00

Is there a role for TPE in managing Vaccine-Induced Immune Thrombotic Thrombocytopenia?
A. Greinacher – Online

11.00-11.15 – O-08: Evaluation of TPE in Pediatric Patients

B. Tutun

11.15-11.30 – O-09: Treatment costs of IVIg versus TPE for GBS, MG and CIPD in inpatient and outpatient settings
N. S. Comasòlivas

11.30-11.45 – O-10: TPE for Management of Maternal Hyperthyroidism Complicated with Fetal Goiter Due to Graves Disease with High T3, Low T4 Pattern
Ü. Mutlu

11.45-12.00 – O-11: Evaluation of Indications, Complications, Outcomes and Hospital Mortality of TPE Applied Patients
T. A. Kırkızlar

12.00-13.00

Sponsored Lunch Symposium

Scientific Session IX
Adsorption Apheresis

Education Session IV
Unique Considerations in Apheresis

Chairs: A. Buser, N. Yalman

Chairs: D. Özatlı, R. Moog

Hall 1

Hall 2

13.00-13.30

H.E.L.P. apheresis
Presenter

Apheresis in pregnancy
C. Webb

13.30-14.00

Use of adsorption techniques in ABO incompatible kidney transplant
H. Vrielink

Apheresis in patients on anticoagulation
R. Sarode

14.00-14.30

Column Immunopheresis® therapy in solid tumors.
P. Wysocki

Apheresis in pediatric patients
B.A. Aksoy

14.30-15.30

Coffee Break & Poster Session 2

Scientific Session X
Turkish Red Crescent

Sceintific Abstract Session 3

Chairs:

Chairs: R. Weinstein, J. Schwartz

Hall 1

Hall 2

15.30-16.00

Blood Services Management in Turkey and the role of the Turkish Red Crescent
MD. Levent Sağdur, Medical Management Director Turkish Red Crescent General Directorate of Blood Services

15.30-15.45 – O-12: Collection of CD3+ Cells in Donors and Patients with Spectra Optia®
H. Vrielink

16.00-16.30

Turkish Red Crescent and Plasma Fractionation
MD. Abdulsettar Yavuz, Plazma Fractionation Unit Manager Turkish Red Crescent General Directorate of Blood Services

15.45-16.00 – O-13: A Prospective Paired Study Comparing the MNC collection Using an in-line Against an off-line ECP Apheresis System
S. Monsalvo

16.30-17.00

NAT practices in Turkish Red Crescent
MD. Mehmet Saygan, Laboratory Management Unit Manager, Central Anatolia Regional Blood Center Directorate

16.00-16.15 – O-14: LW-02 Column Immunopheresis® Therapy Clinical Experience In Refractory Solid Tumors – Removal Of Soluble TNF Receptors (Stnf-Rs) To Promote Antitumor Activity Of Endogenous TNF-Α
R. Segal

16.15-16.30 – O-15: TTP Successfully Treated with Rituximab but with no Presence of ADAMTS13 Antibody
S. O. Sanchez

16.30-16.45 – O-16: Prevention of Hypertriglyceridemia-Induced Acute Pancreatitis in Pregnant State; Lipid Apheresis as a Bridge to Delivery
M. Mastanzade

17.00-17.30

Closing Ceremony – HALL 1

(F. Altuntaş, H. Vrielink, M. Lozano, L. Pierelli)

Presentation of Awards

Introduction of New Board of Directors

19.00-22.00

Gala Dinner (Ticketed Event)

17 September 2022 (Saturday), Day 4

09.00-10.00

WAA Board of Directors Post-Conference Meeting (by invitation only)

ESFH Board of Directors Post-Conference Meeting (by invitation only)

10.00-12.00

Joint Meeting:

· World Apheresis Association Board of Directors

· Hematological Rare Disease Society

· European Society for Hemapheresis

· Sponsors